US FDA approves Novo Nordisk’s Ozempic to cut risk of diabetic kidney disease progression January 28, 2025
ModivCare’s credit rating lowered to ‘CCC+’ at S&P due to persistent collections difficulties January 28, 2025
Stocks Texas Stock Exchange moves closer to launch with leadership team, board September 30, 2024 Post ContentÂ
US FDA approves Novo Nordisk’s Ozempic to cut risk of diabetic kidney disease progression January 28, 2025
English
French
German
Italian
Russian
Spanish
